Versus budesonide

A number of clinical studies have found that Alvesco® is at least as effective as budesonide for the treatment of persistent asthma. One of these studies found that Alvesco® is comparable to budesonide in maintaining forced expiratory volume in one second (FEV1) in patients treated with inhaled corticosteroids (ICSs).1 

However, the second study observed that Alvesco® improves FEV1 (Figure 1), forced vital capacity (FVC) and peak expiratory flow (PEF) significantly more than budesonide in patients in whom ICS therapy has been withdrawn.2 Alvesco® is also associated with an earlier onset of action than budesonide.2

With regards to symptoms, one study found that Alvesco® is associated with more symptom-free days than budesonide,1 while the other one observed similar improvements in both asthma symptom scores and change in rescue medication use (Figure 2).2

223 fig 1Versus budesonide  FEV1 improvement Ukena 2007

Figure 1: Alvesco® improves FEV1 more significantly than budesonide after 12 weeks. Data are presented as least-squares means2

223 fig 2Versus budesonide  asthma symptoms and rescue days Boulet 2006
Figure 2: Alvesco® reduces rescue medication use and is associated with more symptom-free days compared with budesonide1
Reproduced with permission from Elsevier.

  1. Boulet LP, Drollmann A, Magyar P, et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 2006;100:785-94.
  2. Ukena D, Biberger C, Steinijans V, et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther 2007;20:562-70.

Loading ...